Search Results - kenichi+hanada

6 Results

Sort By:

T Cell Receptors Targeting the KRAS G13D Mutation in the Context of HLA-A11:01 for Research Use

Summary: The National Cancer Institute (NCI) has identified HLA-A11:01-restricted T Cell Receptors (TCRs) targeting the KRAS G13D mutation. The NCI seeks licensees for the use of these TCRs in research. Description of Technology: Tumor-specific mutated proteins can create immunogenic, mutation-containing “neoepitopes” which are attractive...

Published: 4/8/2024 | Inventor(s): Catherine Ade, Zhiya Yu, Matthew Sporn, James Yang, Kenichi Hanada

Keywords(s):

Category(s): TherapeuticArea, Application, Application > Research Materials, Collaboration Sought > Licensing

T cell Receptors Which Recognize Mutated EGFR

Abstract: Epidermal growth factor receptor (EGFR) is a transmembrane protein involved in cell growth and proliferation. Mutations in this protein can lead to overexpression, causing several types of cancer; notably, non-small cell lung cancer (NSCLC). For example, mutations in EGFR are found in up to 50% of NSCLC patients and the E746-A750 deletion...

Published: 4/8/2024 | Inventor(s): Kenichi Hanada, Chihao Zhao, Anna Pasetto, James Yang

Keywords(s): EGFR mutation, Epidermal Growth Factor Receptor, Hanada, Immunotherapy, T Cell Receptor, TCR

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics, Collaboration Sought > Collaboration

Extremely Rapid Method to Isolate Neoantigen Reactive T Cell Receptors (TCRs)

Abstract: Adoptive cell transfer (ACT) uses tumor infiltrating lymphocytes (TILs) that recognize unique antigens expressed by cancer cells (“neoantigens”). Neoantigen specific TIL administration in patients has resulted in long term regression of certain metastatic cancers. However, one of the challenges of ACT and engineered T cell receptor (TCR) therapies...

Published: 4/8/2024 | Inventor(s): Sri Krishna, Paul Robbins, Rami Yoseph, James Yang, Kenichi Hanada, Frank Lowery, Steven Rosenberg

Keywords(s): act, Adoptive Cell Transfer, Immunotherapy, Neoantigen, Rosenberg, T Cell Receptor, TCR, TIL, tumor, Tumor Infiltrating Lymphocyte

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology

Neoantigen T Cell Therapy with Neoantigen Vaccination as a Combination Immunotherapy Against Cancer

Abstract: Adoptive cell therapy (ACT) is a breakthrough form of cancer immunotherapy that utilizes autologous, antitumor T cells to attack tumors through recognition of tumor-specific mutations, or neoantigens. A major hurdle in the development of ACT is the exhausted phenotype exhibited by many neoantigen-specific T cells, which limits their efficacy...

Published: 4/8/2024 | Inventor(s): Sri Krishna, Zhiya Yu, Kenichi Hanada, Steven Rosenberg

Keywords(s): act, Adoptive Cell Transfer, Immunotherapy, Krishna, Neoantigen, Rosenberg, T-Cell Receptor, TCR, Vaccine

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics

Novel Murine T-Cell Receptors for Treating Metastatic Thyroid Cancer

Abstract: The occurrence of thyroid cancer has been increasing in the United States. For some patients, with particularly advanced and metastatic cancer, current treatments such as thyroidectomy and adjuvant radioactive iodine therapy can lead to poor outcomes. Hence, there is a need for new thyroid cancer treatments. Researchers at the NCI have developed...

Published: 4/8/2024 | Inventor(s): Kenichi Hanada, Qiong Wang, James Yang, Zhiya Yu

Keywords(s): act, adoptive cell therapy, Human Thyroglobulin, Immunotherapy, METASTATIC, T-cell Receptors, TCR, TCRs, Tg, THYROID CANCER, Yang

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology, Collaboration Sought > Collaboration

T Cell Receptors Targeting BRAF V600E Mutation for Cancer Immunotherapy

Abstract: BRAF is an oncogene that encodinges a serine-threonine kinase (B-Raf kinase) important in regulating cell growth and differentiation. Spontaneous mutations in the BRAF gene allow cells to continuously divide, leading to the development of cancer. A substitution of glutamic acid for valine at amino acid number 600 (designated V600E) accounts...

Published: 8/14/2024 | Inventor(s): Zhiya Yu, Catherine Ade, Matthew Sporn, James Yang, Kenichi Hanada

Keywords(s): BRAF, B-Raf kinase, B-Raf Proto-Oncogene, HLA-A*0301 restriction, Immunotherapy, Rosenberg, serine-threonine kinase, T Cell Receptor, T cell therapy, TCR, V600E mutation, Yang, Yu

Category(s): Application > Therapeutics, Collaboration Sought > Collaboration, TherapeuticArea > Oncology, Collaboration Sought > Licensing